ANDA 218724, held by Novast Labs Ltd. Oxcarbazepine.
As of Nov 16, 2026, ANDA 218724 (Oxcarbazepine), held by Novast Labs Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2025 | Original application | Tentative approval | None posted |
| Oxcarbazepine300MG · tablet, extended release | Oxcarbazepine | None (tentative approval) |
| Oxcarbazepine600MG · tablet, extended release | Oxcarbazepine | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters